Phenotypes Associated with This Genotype

Genotype
MGI:5882422

• Allelic Composition: Tg(EmuSR-HDAC9)1468Kpet/0
• Genetic Background: involves: C57BL/6 * CBA

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

neoplasm

increased leukemia incidence ( J:237420 )

• an additional 20% of mice develop splenic B-cell lymphoma/leukemia (SBCL/L) or another hematological malignancy such as histiocytic sarcoma

increased B cell derived lymphoma incidence ( J:237420 )

• 50% of mice develop B-cell lymphomas

• tumors from spleens show a mature B-cell immunophenotypic profile

• B-cell tumors are primarily of splenic origin with or without nodal involvement and are histologically lymphoproliferative disease (LPD), splenic marginal zone lymphoma (SMZL), and diffuse large B-cell lymphoma (DLBCL)

• an additional 20% of mice develop splenic B-cell lymphoma/leukemia (SBCL/L) or another hematological malignancy such as histiocytic sarcoma

• the lymphomas and lymphoproliferative disorder exhibit both germinal center and post/non-germinal center immunophenotypes

increased splenic marginal zone lymphoma incidence ( J:237420 )

increased histiocytic sarcoma incidence ( J:237420 )

• an additional 20% of mice develop splenic B-cell lymphoma/leukemia (SBCL/L) or another hematological malignancy such as histiocytic sarcoma

mortality/aging

premature death ( J:237420 )

• by 21 months of age, only 48% of mice survive

hematopoietic system

enlarged spleen ( J:237420 )

• 18% of mice exhibit splenomegaly between 6 and 12 months of age

increased B cell number ( J:237420 )

• abnormal B-cell expansion the spleen, indicating development of lymphoproliferative disorder

abnormal spleen marginal zone morphology ( J:237420 )

• splenic marginal zone abnormalities

abnormal lymphocyte physiology ( J:237420 )

• mice develop higher frequency of lymphoproliferations with age compared to controls, such that by 21 months of age, only 48% of mice survive compared to 95% survival in controls

increased B cell proliferation ( J:237420 )

• monoclonal expansions of B-cell proliferations in 2/3 of mice at 8 months of age

immune system

enlarged spleen ( J:237420 )

• 18% of mice exhibit splenomegaly between 6 and 12 months of age

increased B cell number ( J:237420 )

• abnormal B-cell expansion the spleen, indicating development of lymphoproliferative disorder

abnormal spleen marginal zone morphology ( J:237420 )

• splenic marginal zone abnormalities

abnormal lymphocyte physiology ( J:237420 )

• mice develop higher frequency of lymphoproliferations with age compared to controls, such that by 21 months of age, only 48% of mice survive compared to 95% survival in controls

increased B cell proliferation ( J:237420 )

• monoclonal expansions of B-cell proliferations in 2/3 of mice at 8 months of age

cellular

increased B cell proliferation ( J:237420 )

• monoclonal expansions of B-cell proliferations in 2/3 of mice at 8 months of age

growth/size/body

enlarged spleen ( J:237420 )

• 18% of mice exhibit splenomegaly between 6 and 12 months of age

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
non-Hodgkin lymphoma		DOID:0060060	OMIM:605027	J:237420